Abstract
The CDK inhibitor p27 plays a pivotal role in controlling cell proliferation during development, and has been implicated in tumorigenesis. Previous studies have demonstrated changes in p27 protein expression, but not in mRNA levels, in human pituitary tumors. It seems probable that the fall in p27 is due to increased degradation through the ubiquitin-proteasome pathway. Skp2 (S-phase kinase-interacting protein) is a specific F-box protein that allows the recognition and binding of phosphorylated p27 to the ubiquitin complex. The aim of our study was thus to investigate the possible role of Skp2 in pituitary tumorigenesis.
A total of 59 human pituitary samples, 7 normal and 52 adenomas, were assessed for transcriptional expression of Skp2; 51 pituitary samples were assessed for protein expression. Real-time RT-PCR was performed on cDNA of reverse-transcribed mRNA for relative quantification of the Skp2 transcript. Immunostaining was performed using mouse monoclonal anti-Skp2 antibody.
Skp2 mRNA and protein was detectable in every sample studied. Our results showed no significant difference between the pituitary tumors and normal pituitary tissue in Skp2 mRNA or nuclear protein expression. Individual tumor types had similar mRNA expression and variable protein expression. However, samples with high p27 protein expression showed significantly less Skp2 expression than samples with low p27 staining.
Our data suggest that increased p27 degradation through the ubiquitin-proteasome pathway could be regulated in pituitary tumors by changes in Skp2 expression, although other factors probably also play a role.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Nakayama K, Ishida N, Shirane M, et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996;85:707–720.
Kiyokawa H, Kineman RD, Manova-Todorova KO et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 1996;85:721–732.
Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 1998;396:177–180.
Jin L, Qian X, Kulig E et al. Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries. Am J Pathol 1997;151:509–519.
Qian X, Jin L, Grande JP, Lloyd RV. Transforming growth factor-beta and p27 expression in pituitary cells. Endocrinology 1996;137:3051–3060.
Lidhar K, Korbonits M, Jordan S et al. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J Clin Endocrinol Metab 1999;84:3823–3830.
Dahia PL, Aguiar RC, Honegger J et al. Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours. Oncogene 1998;16:69–76.
Korbonits M, Chahal HS, Kaltsas G et al. Expression of phosphorylated p27Kip1 protein and Jab1 (Jun activation domain-binding protein 1) in human pituitary tumors. J Clin Endocrinol Metab 2002;8:2635–2643.
Hershko A, Ciechanover A, Varshavsky A. Basic Medical Research Award. The ubiquitin system. Nat Med 2000;6:1073–1081.
Zhang H, Kobayashi R, Galaktionov K, Beach D. p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase. Cell 1995;82:915–925.
Hershko D, Bornstein G, Ben Izhak O et al. Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 2001;91:1745–1751.
Schulman BA, Carrano AC, Jeffrey PD et al. Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex. Nature 2000;408:381–386.
Sutterluty H, Chatelain E, Marti A et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1999;1:207–214.
Demetrick DJ, Zhang H, Beach DH. Chromosomal mapping of the genes for the human CDK2/cyclin A-associated proteins p19 (SKP1A and SKP1B) and p45 (SKP2). Cytogenet Cell Genet 1996;73:104–107.
Gstaiger M, Jordan R, Lim M et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA 2001;98:5043–5048.
Latres E, Chiarle R, Schulman BA et al. Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci USA 2001;98:2515–2520.
Lin R, Wang TT, Miller WH Jr, White JH. Inhibition of F-Box protein p45(SKP2) expression and stabilization of cyclindependent kinase inhibitor p27(KIP1) in vitamin D analogtreated cancer cells. Endocrinology 2003;144:749–753.
Korbonits M, Chitnis MM, Norman D et al. The release of leptin and its effect on hormone release from human pituitary adenomas. Clin Endocrinol (Oxf) 2001;54:781–789.
Mori M, Mimori K, Shiraishi T et al. p27 expression and gastric carcinoma. Nat Med 1997;3:593
Loda M, Cukor B, Tam SW et al. Increased proteasomedependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231–234.
Catzavelos C, Bhattacharya N, Ung YC et al. Decreased levels of the cell cycle inhibitor p27/kip1 protein: Prognostic implications in primary breast cancer. Nat Med 1997;3:227–230.
Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999;1:193–199.
Marti A, Wirbelauer C, Scheffner M, Krek W. Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation. Nat Cell Biol 1999;1:14–19.
Nakayama K, Nagahama H, Minamishima YA et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J 2000;19:2069–2081.
Signoretti S, Di Marcotullio L, Richardson A et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 2002;110:633–641.
Yang G, Ayala G, Marzo AD et al. Elevated Skp2 protein expression in human prostate cancer: Association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 2002;8:3419–3426.
Penin RM, Fernandez-Figueras MT, Puig L, Rex J, Ferrandiz C, Ariza A. Over-expression of p45(SKP2) in Kaposi's sarcoma correlates with higher tumor stage and extracutaneous involvement but is not directly related to p27(KIP1) downregulation. Mod Pathol 2002;15:1227–1235.
Lim MS, Adamson A, Lin Z et al. Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: Correlation with p27(Kip1) and proliferation index. Blood 2002;100:2950–2956.
Hirai A, Nakamura S, Noguchi Y et al. Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growthstimulated rat FRTL-5 cells. J Biol Chem 1997;272:13–16.
Malek NP, Sundberg H, McGrew S et al. A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase. Nature 2001;413:323–327.
Hara T, Kamura T, Nakayama K, Oshikawa K, Hatakeyama S, Nakayama K. Degradation of p27(Kip1) at the G(0)-G(1) transition mediated by a Skp2-independent ubiquitination pathway. J Biol Chem 2001;276:48937–48943.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Musat, M., Korbonits, M., Pyle, M. et al. The Expression of the F-Box Protein Skp2 is Negatively Associated with p27 Expression in Human Pituitary Tumors. Pituitary 5, 235–242 (2002). https://doi.org/10.1023/A:1025325832698
Issue Date:
DOI: https://doi.org/10.1023/A:1025325832698